We have developed an in vitro transcription system for the epidermal growth factor receptor (EGFR) oncogene by using nuclear extracts of A431 human epidermoid carcinoma cells, which overproduce EGFR. We found that a nuclear factor, termed EGFR-specific transcription factor (ETF), specifically stimulated EGFR transcription by 5-to 10-fold. In this report, ETF, purified by using sequencespecific oligonucleotide affinty chromatography, is shown by renaturing material eluted from a NaDodSO4/polyacrylamide gel to be a protein with a molecular mass of 120 kDa. ETF binds to the promoter region, as measured by DNase I "footprinting" and gel-mobility-shift assays, and specifically stimulates the transcription of the EGFR gene in a reconstituted in vitro transcription system. These results suggest that ETF could play a role in the overexpression of the cellular oncogene EGFR.
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The epidermal growth factor receptor (EGFR) has extensive homology with the erbB oncogene product of the avian erythroblastosis virus (1, 2) . Overproduction of the EGFR has been detected in several types of cancers (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , and it has been shown that overexpression of the EGFR leads to epidermal growth factor-dependent transformation (13, 14) . These results indicate that the EGFR gene can function as an oncogene.
Expression of the EGFR gene is regulated at a variety of levels, including gene amplification (3) (4) (5) (6) (7) (8) (9) (10) (11) and mRNA stability (ref. 9 ; Y. Jinno, G.T.M., and I.P., unpublished data). Very often, the production of EGFR mRNA correlates directly with EGFR levels on the cell surface (9) . Thus, transcriptional control undoubtedly plays a major role in the regulation of the EGFR gene. Therefore, it is possible that a trans-acting factor may transcriptionally activate the EGFR gene in some tumors. Evidence that the protooncogene c-jun encodes the transcription factor AP-1 (15) The promoter of the EGFR gene lacks a "TATA box" and "CAAT box" but contains multiple "GC boxes" (24) . In vitro transcription studies showed that purified transcription factor Spl binds to the GC boxes and stimulates EGFR transcription -4-fold (25) . We also have detected another factor that specifically enhances EGFR transcription but not simian virus 40 (SV40) early transcription (25) . This observation prompted us to characterize and purify this factor. In this study, we describe the purification of a 120-kDa protein that binds to the promoter region of the EGFR gene and specifically stimulates transcription of the EGFR gene, termed EGFR-specific transcription factor (ETF). These results suggest that ETF might be a key factor for the transcriptional activation of this cellular oncogene.
MATERIALS AND METHODS Preparation and Fractionation of A431-Cell Nuclear Extract. Preparation of A431-cell nuclear extracts and their fractionation by heparin-agarose and DEAE-Sepharose CL-6B columns were done as described (25) . The buffer used was HM, which consists of 20 Fig. 3 ). Our minimal in vitro transcription system consisted of fractions BB, BC, and 0.1 M KCI/HM-eluted heparin-agarose fraction A, which contains a stimulating activity.
Fraction BA was purified by sequence-specific oligonucleotide affinity chromatography. The affinity resin was prepared as described by Wu et al. (23) by annealing two oligonucleotides, 5' CCCGCGCGAGCTAGACGTCCGGG-CAGCCCCCGGCGCAGCGCGGCCG 3' and 5' CGGCCG-CGCTGCGCCGGGGGCTGCCCGGACGTCTAG 3'. The 0.5 M KCI fraction was diluted to 0.1 M KCI with HM buffer, reapplied to the column, and eluted as described (25) . The eluates were analyzed with a 10% NaDodSO4/polyacrylamide gel.
In Vitro Transcription. Promoter deletion mutants were made by using restriction enzymes or BAL-31 nuclease and fusing the promoter fragments to the chloramphenicol acetyltransferase (CAT) gene (26) as described (25) . The boundaries of the promoter contained in these plasmids were determined by DNA sequencing (27) . The in vitro reconstitution reaction mixture contained supercoiled templates, heparin-agarose fraction A, DEAE-Sepharose fractions BB and BC in the presence or absence of DEAE-Sepharose fraction BA (see Fig. 3A ). After incubation for 60 min at 30°C, RNA was prepared and hybridized with 5'-end-labeled CATspecific primer. The CAT primer is a synthetic singlestranded 24-mer that hybridizes to the region between residues 4920 and 4943 of pSV2cat (25) . The primer extension product was analyzed on a 5% polyacrylamide sequencing gel. The in vitro major transcription initiation site is at position -48 relative to the translation initiation site.
DNase I "Footprinting." For the coding strand probe, the HindIll fragment of the EGFR promoter region was excised from the template plasmid containing sequence between positions -297 and -20, treated with calf intestinal alkaline phosphatase, 5'-end-labeled with T4 polynucleotide kinase and [-y-32P]ATP, digested with Ava I, and purified from a polyacrylamide gel. For the noncoding strand probe, the Hinfl fragment of the EGFR promoter region was excised from the plasmid containing sequence between positions -388 and -20, 5'-end-labeled, digested with HindIII, and purified from a polyacrylamide gel.
DNase I-footprinting reactions were as described by Dynan and Tjian (28) Gel-Mobility-Shift Assay of Renatured ETF. One microgram of the affinity-purified ETF was separated on a NaDodSO4/polyacrylamide gel, and several protein bands were excised, eluted, and subjected to renaturation as described by Briggs et al. (16) . We added 50 pug of bovine serum albumin in the elution step. Gel-mobility-shift assays were as described by Fried and Crothers (29) . We used the 5'-endlabeled hybridized oligonucleotides as a probe.
RESULTS
Experiments using crude A431-cell nuclear extracts indicated that the promoter region between positions -151 and -20 ( + 1 is the translation initiation site) was sufficient for in vitro EGFR transcription (25) , although in vivo transient CAT expression experiments suggested that regions further upstream were also involved with stimulatory and inhibitory effects on EGFR transcription (30) . We observed that transcription from the plasmids containing the upstream region could be stimulated by reconstitution of fractionated extracts. When the fractions of heparin-agarose and DEAESepharose columns were reconstituted (fractions A + BA + BB + BC) (see Fig. 3A ), the template containing sequence up to position -775 showed about five times more transcription than the template containing sequence up to position -151 (Fig. 1A, lanes 2 and 8) . In addition, it was found that optimal activity of the extended promoter was only achieved in the presence of DEAE-Sepharose fraction BA, which contains ETF (Fig. LA, lanes 1 and 2) . These results suggest that the upstream regions are required for ETF activity. However, additional deletion of sequence from position -256 to position -222 resulted in no stimulation by ETF (Fig. 1B,  lanes 7 and 8) . These (Fig. 2B) .
To purify the factor, we made a sequence-specific oligonucleotide affinity column (23, 31 analyzed by NaDodSO4/polyacrylamide gel electrophoresis.
As shown in Fig. 3B , only a few protein bands remained after this procedure; major bands are 120, 100, and 80 kDa. We then examined the DNA-binding activity and the in vitro transcription activity of affinity-purified ETF. As shown in Fig. 3C , the affinity-purified ETF still protected the region between positions -248 and -233 on a DNase I-footprinting assay. In addition the affinity-purified ETF stimulated EGFR transcription but had no effect on SV40 early transcription (Fig. 3D) . These Fig. 3A ). After incubation for 60 min at 30°C, RNA was prepared and hybridized with 5'-end-labeled CAT-specific primer. The primer extension product was analyzed on a 5% polyacrylamide sequencing gel. (B) More precise localization of the region necessary for ETF activity was determined by a primer-extension assay as described in A. Sequence-specific oligonucleotide affinity resin was prepared as described by Wu Proc., Nad. Acad Sci. USA 85 (1988)
Although affinity-purified ETF still contained several bands, the presence of a 120-kDa protein appeared to be best correlated with the ETF activities (data not shown). To determine if the 120-kDa protein was ETF, regions containing it and other protein bands were excised from an NaDodSO4/ polyacrylamide gel, and the proteins present were eluted and renatured. The ability of the renatured proteins to bind to the EGFR promoter was analyzed by a gel-mobility-shift assay (Fig. 4) . In the presence of the native affinity-purified ETF, a protein-DNA complex migrated with retarded mobility relative to unbound DNA (lane 1). Control experiments showed that the DNA fragment containing the ETF-binding site was able to effectively compete for formation of the complex but nonspecific DNA fragments were not (data not shown). As shown in Fig. 4, only bound to the promoter regions and stimulated EGFR transcription independently. Nonetheless, the possibility of cooperation needs to be examined more carefully because our minimal in vitro transcription system still contained very low but detectable levels of these factors.
The ETF-binding site has an extremely high G + C content (88%). In fact, the center of the sequence consists of only guanosine and cytidine (CCCCCGGC). An identical sequence oriented in the opposite direction is found in the promoter region of the human insulin receptor gene (between residues -43 and -36) (32) . This implies that ETF might regulate other growth factor receptor genes and play an important role in the control of cell growth. Imagawa et al. (22) reported that the consensus sequence recognized by transcription factor AP-2 is YCSCCMNSSS, where Y is thymidine or cytidine, S is cytidine or guanosine, M is adenosine or cytidine, and N is any nucleoside. This site is one of several that appear to be involved in the induction of gene expression by phorbol ester tumor promoters. The sequence of this site matches well with the central sequence ofthe ETF-binding site, raising the possibility that ETF might mediate transcriptional activation by some tumor promoters. However, ETF differs from AP-2 in several important respects. The molecular mass of ETF is 120 kDa, whereas the molecular mass of AP-2 is 50 kDa. Furthermore, ETF has little or no effect on the SV40 promoter, but AP-2 has been shown to stimulate SV40 transcription (21, 22) . Now that a highly purified factor has been obtained it may be possible to understand the precise mechanism of transcriptional activation of the EGFR oncogene.
